Montana has entered uncharted regulatory territory by creating a direct pathway for biotech companies to commercialize experimental drugs with minimal federal oversight. As of this week, any biotech company can pay $12,500 to submit an experimental drug to a newly established state review board for approval, provided the treatment has completed preliminary testing—sometimes involving as few as 10 healthy subjects. This mechanism fundamentally differs from existing 'right to try' laws, which typically allow individual patients with terminal conditions access to experimental treatments outside normal channels. Montana's approach instead creates a commercial market for largely unvalidated drugs, enabling companies to sell directly to consumers without FDA approval. The state's newly formed review board will evaluate applications, though specific details about board composition, medical expertise requirements, and approval timelines remain unclear from available public statements. This regulatory innovation directly challenges the federal FDA's gatekeeping authority over drug safety and efficacy.
The policy emerges from genuine patient desperation. Cases like Brody DeVault, a toddler experiencing severe developmental delays without effective treatments, exemplify the emotional and medical pressure driving such experimental access laws. However, Montana's broader commercialization model carries significant risks. Historical precedents illustrate the dangers: the Lyme disease treatment controversy of the 1990s saw unproven antibiotics harm patients, while unregulated stem cell clinics have caused vision loss and infections in vulnerable patients seeking last-resort treatments. Without rigorous efficacy data, consumers may spend substantial resources on ineffective or genuinely harmful treatments. The $12,500 application fee creates financial incentives for approval rather than safety-focused evaluation, potentially attracting less scrupulous biotech operators seeking quick market entry without comprehensive clinical validation.
The FDA has not publicly commented on Montana's specific framework, but federal officials have long maintained that drug safety requires standardized clinical trials and centralized approval. Industry reaction remains mixed: while some biotech advocates view Montana as a promising innovation hub reducing regulatory burden, established pharmaceutical companies have expressed caution about potential liability and reputational risks. Several other states have signaled interest in studying Montana's model, suggesting this could become a competitive regulatory arbitrage opportunity. This development represents a critical inflection point in the federalism debate over drug approval authority, with profound implications for patient safety standards, drug company liability, and whether other states will follow Montana's precedent, potentially fragmenting the national pharmaceutical regulatory landscape.